DEVELOPMENT STAGE COMPANY Sample Clauses

DEVELOPMENT STAGE COMPANY. Aura recognizes Ontro is a development stage company, that it has an accumulated deficit and a working capital deficit, has not generated any revenue from operations and is not expected to generate any revenue from operations for some time and perhaps for years, and that proposed development expenditures are expected to result in substantial and increasing losses over at least the next several years, and possibly much longer. Investment in Ontro involves substantial risk, and Aura should not acquire the Warrants unless it can afford the complete loss of its investment. Aura has taken full cognizance of and understands all of the risk factors related to the receipt of the Warrants.
Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
DEVELOPMENT STAGE COMPANY. The Investor recognizes the Company is a development stage Company, that it has an accumulated deficit and a working capital deficit, has not generated any revenue from operations and is not expected to generate any revenue from operations for some time and perhaps for years, and that proposed development expenditures are expected to result in substantial and increasing losses over at least the next one or more years, and possibly much longer. Investment in the Company involves substantial risk, and the Investor can afford the complete loss of its investment. The Investor has taken full cognizance of and understands all of the risk factors related to the receipt of the Common Stock.
Sample 1Sample 2Sample 3See All (5)
DEVELOPMENT STAGE COMPANY. The Company is a development stage company without any operating history. There can be no assurance that the Company will be able to implement its business plan, raise sufficient capital to fund its development or achieve a level of operating revenues or income sufficient to enable the Company to continue as a going concern. It has no commercial products and its products in development require significant further research, development, testing, and regulatory clearances and are subject to the risks of failure inherent in the development of products based on new technologies. These risks include the possibilities that the Company’s technology or any or all of its product candidates will be found to be unsafe, ineffective or toxic, especially in immunosuppressed individuals, or fail to receive necessary regulatory clearances to develop or approve the products; that the product candidates, even if found to be safe and effective, will be difficult to manufacture on a large scale or uneconomical to market; that the product candidates will be stable enough for commercialization; that proprietary rights of third parties will preclude the Company from marketing products; or that third parties will market superior or equivalent products. There can be no assurance that the Company’s research and development activities will result in any commercially viable products.
Sample 1Sample 2Sample 3
DEVELOPMENT STAGE COMPANY. The undersigned recognizes Ontro is a development stage company, that it has an accumulated deficit and a working capital deficit, has not generated any revenue from operations and is not expected to generate any revenue from operations for some time and perhaps for years, and that proposed development expenditures are expected to result in substantial and increasing losses over at least the next several years, and possibly much longer. Investment in Ontro involves substantial risk, and the undersigned should not acquire the Common Stock unless he or she can afford the complete loss of their investment. The undersigned has taken full cognizance of and understands all of the risk factors related to the receipt of the Common Stock.
Sample 1
DEVELOPMENT STAGE COMPANY. The Purchaser acknowledges and understands that the Company is a development-stage company.
Sample 1Sample 2
DEVELOPMENT STAGE COMPANY. Stockholder understands fully that the Company is a development-stage company. There can be no assurance that the Company will generate any revenues, or if revenues are generated, that the Company can sustain revenues for any period of time or otherwise achieve or maintain profitability.
Sample 1
DEVELOPMENT STAGE COMPANY. The Purchaser acknowledges and understands that the Company commenced operations in 1997.
Sample 1
AutoNDA by SimpleDocs
DEVELOPMENT STAGE COMPANY. As a development stage company, the Company’s book value is dependent on its continuation as a going concern. Furthermore, the Company anticipates that it will generate an operating deficit during its initial operation. The Company intends to sub-license its portfolio products and technology to prospective customers, to commercialize the P3D technology in Europe, and to raise, or generate from operations, sufficient capital to continue as a going concern. The value of the Company’s assets would materially decrease were it to be unable to continue as a going concern.
Sample 1

Related to DEVELOPMENT STAGE COMPANY

  • Development Efforts 4.2.1 Hana shall use Commercially Reasonable Efforts to Develop each Product in the Territory (including carrying out its responsibilities under the Development Plan) to:

  • Development Diligence Pfizer will use its Commercially Reasonable Efforts to Develop and seek Regulatory Approval for [ * ] Product [ * ] in the Field [ * ]. Pfizer will [ * ] with respect to the Development or Regulatory Approval of Products under this Agreement.

  • Development Plan As defined in Section 3.2(a).

  • Development Program A. Development Activities to be Undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Initial Development Plan Not later than the Effective Date, Licensee shall have provided Merck with an initial Development plan for the Licensed Product in the Field in the Territory, which shall be incorporated as part of this Agreement as Attachment 3.02(a) (as may be amended in accordance with this Agreement, the “Development Plan”). **CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  • Development Activities NovaDel shall not be required to commence any Development Activities until Licensee has paid at least twenty-five percent (25%) of the non-refundable License Fee described in Section 4.4.

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Development Schedule The schedule for design and development of the "BASE BUILDING WORK" (as defined below) and the "TENANT IMPROVEMENTS" (as defined below), including, without limitation, the time periods for preparation, delivery, review, and approval of construction documents and performance pursuant to such documents, shall be in accordance with the Development Schedule attached hereto as Schedule A, subject to adjustment as mutually agreed by the parties in writing or as provided in this Work Letter (the "DEVELOPMENT SCHEDULE").

  • Development and Regulatory Milestones With respect to each of the following milestones, Ikaria shall pay BioLineRx the corresponding payment set forth below within [**] days after the achievement by Ikaria, its Affiliates or Licensees of such milestone: MILESTONE PAYMENT

  • Commercialization Plans As soon as practicable after formation of the JCC (following Acucela’s exercise of an Opt-In Right under Section 3.1), the JCC shall prepare and approve the initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation (and, if applicable, any New Formulation or Other Indication Product) in the Territory. The Parties shall use Commercially Reasonable Efforts to ensure that such initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation is consistent with the general Commercialization Plan outline set forth in Exhibit C attached hereto and incorporated herein (the “General Commercialization Plan Outline”). The JCC shall prepare and approve a separate Commercialization Plan for Commercialization of Licensed Product for the Initial Indication in the Initial Formulation in the Territory and for Commercialization of each Other Indication Product and New Formulation (if any) in the Territory, and shall update and amend each Commercialization Plan not less than annually or more frequently as needed to take into account changed circumstances or completion, commencement or cessation of Commercialization activities not contemplated by the then-current Commercialization Plan. Amendments and revisions to the Commercialization Plan shall be reviewed and discussed, in advance, by the JCC, and Otsuka agrees to consider proposals and suggestions made by Acucela regarding amendments and revisions to the Commercialization Plan. Any amendment or revision to the Commercialization Plan that provides for an increase or decrease in the number of FTEs for any Phase 3b Clinical Trials or Post-Approval Studies as compared to the previous version of the Commercialization Plan, or that provides for addition or discontinuation of tasks or activities as compared to the previous version of the Commercialization Plan, or that moves forward the timetable for activities reflected in the Commercialization Plan, shall provide for a reasonable ramp-up or wind-down period, as applicable, to accommodate a smooth and orderly transition of Commercialization activities to the amended or revised Commercialization Plan. Each Commercialization Plan shall identify the goals of Commercialization contemplated thereunder and shall address Commercialization (including Co-Promotion) activities related to the Licensed Product (including, if applicable, any Other Indication Product), including:

Time is Money Join Law Insider Premium to draft better contracts faster.